Pharmaceutical use of Echinacoside for treatment of hypoxic-ischemic encephalopathy

An echinacoside, hypoxia-ischemia technology, applied in cardiovascular system diseases, medical preparations containing active ingredients, drug combinations, etc., to achieve the effects of reducing neuronal apoptosis rate, inhibiting Caspase3, and reducing oxidative damage

Active Publication Date: 2019-03-29
NINGXIA MEDICAL UNIV
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the in vivo study of the effect of echinacoside on hypoxic-ischemic encephalopathy has not been reported in the literature, so it has extremely high potential value and social significance to develop it as a therapeutic drug for neonatal hypoxic-ischemic encephalopathy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical use of Echinacoside for treatment of hypoxic-ischemic encephalopathy
  • Pharmaceutical use of Echinacoside for treatment of hypoxic-ischemic encephalopathy
  • Pharmaceutical use of Echinacoside for treatment of hypoxic-ischemic encephalopathy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] The pharmaceutical use of echinacoside as a treatment for neonatal hypoxic-ischemic encephalopathy, wherein neonatal hypoxic-ischemic brain injury is acute ischemic-hypoxic brain injury, and the single application dose of echinacoside is 40 mg for neonatal rats / Kg, the dosage form of the drug is an injection dosage form.

Embodiment 2

[0034] The pharmaceutical use of echinacoside as a treatment for neonatal hypoxic-ischemic encephalopathy, wherein neonatal hypoxic-ischemic brain injury is the repair period of ischemic-hypoxic brain injury, and the single application dose of echinacoside is 80 mg for neonatal rats / Kg, the dosage form of medicine is powder injection dosage form.

Embodiment 3

[0036] The pharmaceutical use of echinacoside as a treatment for neonatal hypoxic-ischemic encephalopathy, wherein neonatal hypoxic-ischemic encephalopathy is ischemic-hypoxic brain injury in the repair period, and the single application dose of echinacoside is 160 mg for neonatal rats / Kg, the dosage form of medicine is powder injection dosage form.

[0037] The following animal experiment has further illustrated the effect of above-mentioned embodiment 1 to 3:

[0038] 1. Experimental materials

[0039] 1.1 Animal handling

[0040] 120 7-day-old SD rats (12-17g) were purchased from the Experimental Animal Center of Ningxia Medical University, animal production license number: SCXK (Ning) 2015-0001. Animals were placed in a temperature (22-24°C) and humidity (40-70%) controlled environment with free access to food and water under a 12h / 12h light / dark cycle. Before the experiment, the animals were placed in the experimental environment for 3 days to adapt.

[0041] 1.2 Exp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses pharmaceutical use of Echinacoside (ECH) for treatment of hypoxic-ischemic encephalopathy. The experimental results of the present invention indicate that the Etoposideat a dose of 160 mg / kg can significantly improve cerebral infarction volume and neuronal damage and apoptosis in a hypoxic-ischemic model of neonatal rats when used in a safe dose range, and prove that the Etoposide can promote the recovery of neuronal ischemia and hypoxia injury and prevent disability and death after hypoxic ischemic encephalopathy.

Description

technical field [0001] The invention relates to the application of echinacoside, in particular to the pharmaceutical use of echinacoside for treating neonatal hypoxic-ischemic encephalopathy. Background technique [0002] Neonatal hypoxic-ischemic encephalopathy (hypoxic-ischemic brain damage, HIBD) is one of the most common central nervous system diseases in fetuses and newborns worldwide, and it is also a major factor in its mortality and morbidity. It leads to acute death and chronic neurological dysfunction in children, such as cerebral palsy, restlessness, epilepsy, school-age intelligence and low memory, etc., seriously affecting children, families and society. In developed countries, the incidence of neonatal hypoxic-ischemic encephalopathy is 1-8‰, while in developing countries it is as high as 26‰. Although medical workers currently have various interventions and treatments for neonatal hypoxic-ischemic encephalopathy method, but its morbidity and mortality are sti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P25/28A61P9/10
CPCA61K31/7048A61P9/10A61P25/28
Inventor 余建强魏炜刘宁杨佳美张文晋马琳田甜李玉香
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap